Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (23.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 23.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compens |
| 21.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | June 30, 2025 and other information described in Item 5.02 below. A copy of the press release is furnished as Exhibit 99 |
| 05.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 06.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 05.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certa |
| 08.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
Stammdaten
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Unternehmen & Branche
| Name | GLOBUS MEDICAL INC |
|---|---|
| Ticker | GMED |
| CIK | 0001237831 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 12,31 Mrd. USD |
| Beta | 1,09 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 2,938,931,000 | 537,868,000 | 3.92 | 5,302,761,000 | 4,573,250,000 |
| 2025-09-30 | 10-Q | 769,048,000 | 118,966,000 | 0.88 | 5,095,640,000 | 4,398,825,000 |
| 2025-06-30 | 10-Q | 745,342,000 | 202,846,000 | 1.49 | 4,961,089,000 | 4,295,683,000 |
| 2025-03-31 | 10-Q | 598,121,000 | 75,462,000 | 0.54 | 4,711,148,000 | 4,088,068,000 |
| 2024-12-31 | 10-K | 2,519,355,000 | 102,984,000 | 0.75 | 5,251,750,000 | 4,177,333,000 |
| 2024-09-30 | 10-Q | 625,705,000 | 51,836,000 | 0.38 | 5,086,044,000 | 4,069,397,000 |
| 2024-06-30 | 10-Q | 629,691,000 | 31,760,000 | 0.23 | 4,993,793,000 | 3,976,365,000 |
| 2024-03-31 | 10-Q | 606,666,000 | -7,117,000 | -0.05 | 4,943,612,000 | 3,922,361,000 |
| 2023-12-31 | 10-K | 1,568,476,000 | 122,873,000 | 1.07 | 5,086,083,000 | 3,997,959,000 |
| 2023-09-30 | 10-Q | 383,639,000 | 998,000 | 0.01 | 5,355,875,000 | 4,187,285,000 |
| 2023-06-30 | 10-Q | 291,615,000 | 57,712,000 | 0.57 | 2,212,465,000 | 1,985,065,000 |
| 2023-03-31 | 10-Q | 276,688,000 | 49,129,000 | 0.48 | 2,149,620,000 | 1,914,820,000 |
| 2022-12-31 | 10-K | 1,022,843,000 | 190,169,000 | 1.85 | 2,076,126,000 | 1,846,373,000 |
| 2022-09-30 | 10-Q | 254,148,000 | 47,431,000 | 0.47 | 1,976,512,000 | 1,764,111,000 |
| 2022-06-30 | 10-Q | 263,648,000 | 54,590,000 | 0.53 | 1,914,712,000 | 1,699,093,000 |
| 2022-03-31 | 10-Q | 230,549,000 | 38,084,000 | 0.37 | 1,998,694,000 | 1,785,372,000 |
| 2021-12-31 | 10-K | 958,102,000 | 149,191,000 | 1.44 | 1,957,263,000 | 1,741,388,000 |
| 2021-09-30 | 10-Q | 229,721,000 | 47,211,000 | 0.45 | 1,910,578,000 | 1,718,269,000 |
| 2021-06-30 | 10-Q | 251,016,000 | 41,545,000 | 0.40 | 1,830,213,000 | 1,639,273,000 |
| 2021-03-31 | 10-Q | 227,344,000 | 45,329,000 | 0.44 | 1,737,890,000 | 1,562,994,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-08 | Norwalk Leslie V | Director | Open Market Sale | -2,000 | 101.10 | -202,200.00 | -51,6% | |
| 2025-12-12 | Norwalk Leslie V | Director | Open Market Sale | -4,000 | 88.85 | -355,400.00 | -90,7% | |
| 2025-11-10 | RHOADS ANN D | Director | Open Market Sale | -2,000 | 85.00 | -170,000.00 | -43,4% | |
| 2025-11-07 | RHOADS ANN D | Director | Open Market Sale | -8,000 | 81.00 | -648,000.00 | -165,3% | |
| 2025-09-15 | RHOADS ANN D | Director | Open Market Sale | -10,000 | 58.46 | -584,600.00 | -149,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.